Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.
Sentynl Therapeutics, Inc completed the acquisition of Global rights to Zokinvy from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million on May 3, 2024.